Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.
A small and financially opaque drug research nonprofit group based in Ohio has managed to get its research cited extensively ...
GlobalData on MSN1d
Royalty Pharma pays $250m for rights to Biogen’s lupus drugRoyalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
Recently, a letter to the editor I wrote was published in the Arkansas Democrat-Gazette on the subject of skyrocketing health-care costs, inclusive of rising pharmaceutical drug prices. I referenced ...
Swedish biotech company Gesynta Pharma AB has secured $27million in a Series B financing round led by Innovestor Life Science in Finland.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback